Medication to prevent anthracycline cardiotoxicity - Intro

Medication to prevent anthracycline cardiotoxicityПодробнее

How does oncology drug induce cardiotoxicity? Overview: mechanism & clinical guidelines (ESMO) 2022Подробнее

Intro to Cardio-Oncology (Barry Trachtenberg, MD) June 17, 2020Подробнее

Mechanism-based Serum Peptidomic Study in Anthracycline Cardiotoxicity PreventionПодробнее

Anthracycline Cardiotoxicity: The Role of Cardio-Oncology in ManagementПодробнее

Cardiovascular Recovery in Anthracycline CardiotoxicityПодробнее

Anthracycline CardiotoxicityПодробнее

Cardiotoxicities of antineoplastic medicationsПодробнее

JCM Webinar | Updates on Cardiac and Vascular Toxicities from Antineoplastic DrugsПодробнее

Benefits and drawbacks of dexrazoxaneПодробнее

Anthracycline CardiotoxicityПодробнее

Pharmacogenomic Prediction of Antracycline-induced CardiotoxicityПодробнее

Cardiac Toxicities of Breast Cancer Treatment: Pathophysiology, Prevention, and TreatmentПодробнее

Anthracycline Cardiotoxicity: Clinical TypesПодробнее

Search for Biomarkers for Anthracycline Cardio-Toxicity (BARRY TRACHTENBERG, MD) October 18, 2017Подробнее

What is the mechanism of dexrazoxane?Подробнее

Dexrazoxane - Totect - Zinecard In anutshell.Подробнее

Dr. Rosendo - "Chemotherapy Associated Toxicity"Подробнее

Cardio-Oncology: What do we know beyond anthracycline cardiotoxicity, Dr. Lili ZhangПодробнее